Clinical Trial Update: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating short-course radiation with TASOX (TAS102 plus oxaliplatin) chemotherapy in operable rectal cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• TAS102 (trifluridine/tipiracil)

Snippet

Sponsor: Providence Health & Services | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-10